Myocardial InfarctionMaraCat2NCT06000930
Cardiac Troponin Fragmentation After Heavy Physical Exercise The MaraCat2 Study
An observational study of Myocardial Infarction and Myocardial Injury, run by University of Turku at 1 site in Finland.
Trial summary
Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Myocardial Infarction, Myocardial Injury
- What is being tested?
- Troponin fragmentation
- How many people
- 170 participants
- Where
- 1 siteFinland
- Study dates
- 19 Aug 2023to 1 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Marathon runners and patients with acute myocardial infarction as a control group
Who may be able to join
- participating marathon race or treated for Type 1 myocardial infarction and giving informed consent
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may cause troponin elevation after exercise and lead to false diagnosis of MI.
In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.
Read more
A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited. All participants give a blood sample during the post-race visit (within 30 min after finishing the marathon).
A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital.
Commercial cTnT and long troponin component of cTnT analyzed witha novel immunoassay are dtermined in all subjects to assess cTnT fragmentation. TYhe main aims of the study are:
To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin more common after marathon race compared with Type 1 MI and can the novel Supertropo test separate execise-induced troponin rise from those caused by MI ?
Read the detailed description
Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury.
Based on a small gel filtration chromatography study the released troponin in this condition seems to be predominantly in the form of small fragments. These smaller cytosolic troponin fragments may more easily traverse across cell membranes that have become leaky but not irreversibly damaged. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may lead to false diagnosis of MI.
In a Proof-of-Principle study we developed a novel immunoassay which is much simpler and more sensitive than previously used laboratory methods for studying cTnT fragmentation. In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.
A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited to the MaraCat2 Study with an open email invitation. All participants give a blood sample during the post-race visit (within 60 min after finishing the marathon).
A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital. Coronary angiography is performed in all included patients to confirm culprit lesion and the MI diagnosis. All included patients are treated with primary or urgent percutaneous coronary intervention. Only patients with <24 delay from symptom onset to blood sample are included to avoid the effects of later gradual fragmentation of cTnT in the circulation.
Certified laboratory services by Turku University Hospital (TYKSLAB) take care of blood samples. After centrifugation, serum is aliquoted, frozen and stored at -70 °C for later analysis. Analysis is performed on a single day using the same calibration and set-up to minimize variation.
cTnT was analyzed using a commercial high-sensitive assay (Roche Diagnostics GmbH, Mannheim, Germany).
A novel sensitive time-resolved immunofluorometric assay is used for the detection of long cTnT forms (long cTnT). The long cTnT assay follows the sandwich type immunoassay format and utilizes time-resolved-fluorescence (TRF) as the measurement platform.
The main aims of the study are:
To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin complex (assessed by long cTnT/ total cTnT ratio) more common after marathon race compared with Type 1 MI? Is the novel Supertropo test able to separate exercise-induced troponin elevations from those caused by MI ? All participants provide written informed consent. The study complies with Declaration of Helsinki as revised in 2002 and the study protocol was approved by the Medical Ethics Committee of the Hospital District of Southwest Finland.
Statistical analysis Continuous variables are reported as mean ± standard deviation when normally distributed, and as median [inter-quartile range (IQR)] if they were skewed unless stated otherwise. The normality of the data distribution is examined by the Shapiro-Wilk test. Statistical significance was assumed at a p value < 0.05. Categorical variables were described with absolute and relative (percentage) frequencies. Chi-squared test and Fisher's exact test are used for categorical variables as appropriate. Independent samples t-test and Mann-Whitney U test are used for univariate analysis. Correlation between continuous variables are estimated using the Spearman test. Linear regression analysis with backward selection is used to identify factors significantly relating to post-race cTnT levels. All predictors with a P value < 0.1 in univariate analysis were included in the final regression model.
- Conditions
- Myocardial Infarction, Myocardial Injury
- Being tested
- Troponin fragmentation
- Keywords
- exercise, troponin, myocardial infarction, myocardial injury
- Medical subject headings
- Myocardial Infarction, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Troponin fragmentationDiagnostic test
laboratory test from blood sample
| Study group | Role | What they receive |
|---|---|---|
| marathon runners | Marathon runners Receives: Diagnostic Test: Troponin fragmentation | |
| myocardial infarction | Patients with Type 1 myocardial infarction Receives: Diagnostic Test: Troponin fragmentation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Magnitude of Troponin fragmentation in the post-race and post-MI (<24h) blood samples
Ratio of long troponin component to total troponin T in the post-race and post-MI (<24h) blood sample
Measured: < 1 hour after marathon race and < 24 hours after myocardial infarction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2023
- Study start19 Aug 2023
- Primary completion1 Sep 2024 (estimated)
- Study completion1 Sep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 170 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Turku
- Sponsor type
- University, hospital or other
- Collaborators
- Turku University Hospital
- Responsible party
- Principal investigator, Juhani Airaksinen, University of Turku
- Investigators
- Juhani K Airaksinen, Md, PhD, Principal investigator, Turku University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06000930
- Sponsor's protocol ID
- 13.06.2023/207
- Acronym
- MaraCat2
- Status last verified
- May 2024
- First submitted
- 13 Aug 2023
- Last updated
- 8 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Airaksinen KEJ, Paana T, Vasankari T, Salonen S, Tuominen T, Linko-Parvinen A, Pallari HM, Hellman T, Teppo K, Heinonen OJ, Jaakkola S, Wittfooth S. Composition of cardiac troponin release differs after marathon running and myocardial infarction. Open Heart. 2024 Nov 17;11(2):e002954. doi: 10.1136/openhrt-2024-002954.
PubMed 39551608
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiac Troponin Fragmentation After Heavy Physical Exercise The MaraCat2 Study
- ClinicalTrials.gov ID
- NCT06000930
- Acronym / sponsor ID
- MaraCat2 / 13.06.2023/207
- Conditions
- Myocardial Infarction, Myocardial Injury
- Keywords
- exercise, troponin, myocardial infarction, myocardial injury
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 170 participants (estimated)
- Lead sponsor
- University of TurkuUniversity, hospital or other
- Collaborators
- Turku University Hospital
- Study start
- 19 Aug 2023 (actual)
- Primary completion
- 1 Sep 2024 (estimated)
- Study completion
- 1 Sep 2024 (estimated)
- First posted
- 21 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may cause troponin elevation after exercise and lead to false diagnosis of MI.
In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.
A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited. All participants give a blood sample during the post-race visit (within 30 min after finishing the marathon).
A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital.
Commercial cTnT and long troponin component of cTnT analyzed witha novel immunoassay are dtermined in all subjects to assess cTnT fragmentation. TYhe main aims of the study are:
To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin more common after marathon race compared with Type 1 MI and can the novel Supertropo test separate execise-induced troponin rise from those caused by MI ?
Detailed description
Cardiac troponins are highly sensitive and specific biomarkers of cardiac injury and are in a key role in the diagnosis of acute myocardial infarction (MI). Minor troponin elevations are common after prolonged strenuous exercise without clinical symptoms of MI or myocardial injury.
Based on a small gel filtration chromatography study the released troponin in this condition seems to be predominantly in the form of small fragments. These smaller cytosolic troponin fragments may more easily traverse across cell membranes that have become leaky but not irreversibly damaged. Importantly, currently used high-sensitivity troponin T (cTnT) test detects also smaller troponin fragments which may lead to false diagnosis of MI.
In a Proof-of-Principle study we developed a novel immunoassay which is much simpler and more sensitive than previously used laboratory methods for studying cTnT fragmentation. In the present study protocol, we compare the characteristics troponin release after marathon race and Type 1 MI with the improved version of our novel troponin fragmentation test (SuperTropo test) and the commercial cTnT test.
A total of 65 recreational runners participating in the 2023 Paavo Nurmi Marathon in Turku are recruited to the MaraCat2 Study with an open email invitation. All participants give a blood sample during the post-race visit (within 60 min after finishing the marathon).
A control group of 90 patients with acute Type 1 MI are recruited among patients admitted to Heart Centre of Turku University Hospital. Coronary angiography is performed in all included patients to confirm culprit lesion and the MI diagnosis. All included patients are treated with primary or urgent percutaneous coronary intervention. Only patients with <24 delay from symptom onset to blood sample are included to avoid the effects of later gradual fragmentation of cTnT in the circulation.
Certified laboratory services by Turku University Hospital (TYKSLAB) take care of blood samples. After centrifugation, serum is aliquoted, frozen and stored at -70 °C for later analysis. Analysis is performed on a single day using the same calibration and set-up to minimize variation.
cTnT was analyzed using a commercial high-sensitive assay (Roche Diagnostics GmbH, Mannheim, Germany).
A novel sensitive time-resolved immunofluorometric assay is used for the detection of long cTnT forms (long cTnT). The long cTnT assay follows the sandwich type immunoassay format and utilizes time-resolved-fluorescence (TRF) as the measurement platform.
The main aims of the study are:
To assess how often cTnT is elevated after marathon running and which factors affect the cTnT rise? Is the fragmentation of troponin complex (assessed by long cTnT/ total cTnT ratio) more common after marathon race compared with Type 1 MI? Is the novel Supertropo test able to separate exercise-induced troponin elevations from those caused by MI ? All participants provide written informed consent. The study complies with Declaration of Helsinki as revised in 2002 and the study protocol was approved by the Medical Ethics Committee of the Hospital District of Southwest Finland.
Statistical analysis Continuous variables are reported as mean ± standard deviation when normally distributed, and as median [inter-quartile range (IQR)] if they were skewed unless stated otherwise. The normality of the data distribution is examined by the Shapiro-Wilk test. Statistical significance was assumed at a p value < 0.05. Categorical variables were described with absolute and relative (percentage) frequencies. Chi-squared test and Fisher's exact test are used for categorical variables as appropriate. Independent samples t-test and Mann-Whitney U test are used for univariate analysis. Correlation between continuous variables are estimated using the Spearman test. Linear regression analysis with backward selection is used to identify factors significantly relating to post-race cTnT levels. All predictors with a P value < 0.1 in univariate analysis were included in the final regression model.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| marathon runners | – | Diagnostic Test: Troponin fragmentationMarathon runners |
| myocardial infarction | – | Diagnostic Test: Troponin fragmentationPatients with Type 1 myocardial infarction |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Marathon runners and patients with acute myocardial infarction as a control group
Key inclusion criteria (1 listed)
- participating marathon race or treated for Type 1 myocardial infarction and giving informed consent
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Troponin fragmentationlaboratory test from blood sample | Diagnostic test | marathon runners, myocardial infarction |
Primary outcome
Magnitude of Troponin fragmentation in the post-race and post-MI (<24h) blood samples
Time frame: < 1 hour after marathon race and < 24 hours after myocardial infarction
Ratio of long troponin component to total troponin T in the post-race and post-MI (<24h) blood sample
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2024.
- Derived from this study: PubMed 39551608Airaksinen KEJ, Paana T, Vasankari T, Salonen S, Tuominen T, Linko-Parvinen A, Pallari HM, Hellman T, Teppo K, Heinonen OJ, Jaakkola S, Wittfooth S. Composition of cardiac troponin release differs after marathon running and myocardial infarction. Open Heart. 2024 Nov 17;11(2):e002954. doi: 10.1136/openhrt-2024-002954.
- Individual participant dataSharing planned: Undecided
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juhani K Airaksinen, Md, PhD principal investigator
Turku University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Infarction and Myocardial Injury, run by University of Turku at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Magnitude of Troponin fragmentation in the post-race and post-MI (<24h) blood samples (time frame: < 1 hour after marathon race and < 24 hours after myocardial infarction). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06000930, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2024.